Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

INTRODUCTION: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with h...

Descripción completa

Detalles Bibliográficos
Autores principales: Horváth-Puhó, Erzsébet, Suttorp, Marit M, Frederiksen, Henrik, Hoekstra, Tiny, Dekkers, Olaf M, Pedersen, Lars, Cannegieter, Suzanne C, Dekker, Friedo W, Sørensen, Henrik Toft
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167129/
https://www.ncbi.nlm.nih.gov/pubmed/30310329
http://dx.doi.org/10.2147/CLEP.S172306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167129/
https://www.ncbi.nlm.nih.gov/pubmed/30310329
http://dx.doi.org/10.2147/CLEP.S172306

Ejemplares similares